Aluminum administration in the Rat separately affects the osteoblast and Bone mineralization

Rodriguez, Mariano; Felsenfeld, Arnold J.; Llach, Francisco

doi:10.1002/jbmr.5650050110

Cited by 74 publications

(48 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Briefly, with the rat under general anesthesia (Sevofluorane, Abbott, Madrid, Spain), the skin on the ventral part of the neck was incised; the thyroid was exposed; and the parathyroid glands were identified, dissected, and ablated. Hemorrhage was prevented by electrocautery.…”

Section: Concise Methodsmentioning

confidence: 99%

Calcium Deficiency Reduces Circulating Levels of FGF23

Rodríguez‐Ortiz

López²,

Muñoz‐Castañeda³

et al. 2012

Journal of the American Society of Nephrology

Self Cite

194

106

View full text Add to dashboard Cite

Fibroblast growth factor (FGF) 23 inhibits calcitriol production, which could exacerbate calcium deficiency or hypocalcemia unless calcium itself modulates FGF23 in this setting. In Wistar rats with normal renal function fed a diet low in both calcium and vitamin D, the resulting hypocalcemia was associated with low FGF23 despite high parathyroid hormone (PTH) and high calcitriol levels. FGF23 correlated positively with calcium and negatively with PTH. Addition of high dietary phosphorus to this diet increased FGF23 except in rats with hypocalcemia despite high PTH levels. In parathyroidectomized rats, an increase in dietary calcium for 10 days increased serum calcium, with an associated increase in FGF23, decrease in calcitriol, and no change in phosphorus. Also in parathyroidectomized rats, FGF23 increased significantly 6 hours after administration of calcium gluconate. Taken together, these results suggest that hypocalcemia reduces the circulating concentrations of FGF23. This decrease in FGF23 could be a response to avoid a subsequent reduction in calcitriol, which could exacerbate hypocalcemia. 23: 119023: -119723: , 201223: . doi: 10.1681 Fibroblast growth factor (FGF) 23 production is stimulated by both calcitriol and phosphorus intake. FGF23 acts through FGFR-klotho receptors in the kidney to induce phosphaturia, a decrease in 1-a-hydroxylase activity, and an increase in 24-hydroxylase activity. The latter two effects decrease the synthesis and increase the degradation of calcitriol, respectively. 1-4 Parathyroid cells also possess FGFR-klotho receptors, and experimental studies have shown that FGF23 inhibits parathyroid hormone (PTH) production and secretion. [5][6][7] However, in uremic animals, hyperplastic parathyroid glands fail to respond to FGF23 because the expression of FGFR-klotho is downregulated. [7][8][9][10][11] FGF23 effectively increases the output and decreases the input of phosphorus because it directly increases phosphaturia and indirectly decreases intestinal phosphorus absorption by decreasing calcitriol values. However, a conflict will arise if high FGF23 inhibits calcitriol production in a setting of calcium deficiency/hypocalcemia, where high calcitriol is needed to increase intestinal calcium absorption. We have previously observed in parathyroidectomized (PTX) rats with decreased serum J Am Soc Nephrol

show abstract

Section: Concise Methodsmentioning

confidence: 99%

Calcium Deficiency Reduces Circulating Levels of FGF23

Rodríguez‐Ortiz

López²,

Muñoz‐Castañeda³

et al. 2012

Journal of the American Society of Nephrology

Self Cite

194

106

View full text Add to dashboard Cite

show abstract

“…Later, Blades et al (1998) conducted in vivo animal study on aluminumcontaining glass ionomer cements (GICs) as potential bone cements, where as low as 1 ppm of aluminum released was found to inhibit mineralization of the newly formed osteoid in rabbit bone. It is important to distinguish that the role of aluminum in Blades et al (1998) study may be attributed to aluminum toxicity to bone-forming cells (Rodriguez et al, 1990) and direct inhibition of crystal growth as opposed to reduced bioactivity involving structural parameters of the residual glass phase, as proposed in Strnad (1992) study.…”

Section: Biomedical Applications Of Apatite Glass-ceramics Orthopedicsmentioning

confidence: 99%

Apatite Glass-Ceramics: A Review

2017

View full text Add to dashboard Cite

This article is a review of the published literature on apatite glass-ceramics (GCs). Topics covered include crystallization mechanisms of the various families of apatite GCs and an update on research and development on apatite GCs for applications in orthopedics, dentistry, optoelectronics, and nuclear waste management. Most apatite GCs crystallize through a homogenous nucleation and crystallization mechanism, which is aided by a prior liquid-liquid phase separation. Careful control of the base glass composition and heat-treatment conditions, which determine the nature and morphology of the crystal phases in the GC can produce GC materials with exceptional thermal, mechanical, optical, and biological properties. The GCs reviewed for orthopedic applications exhibit suitable mechanical properties and can chemically bond to bone and stimulate its regeneration. The most commercially successful apatite GCs are those developed for dental veneering. These materials exhibit excellent translucency and clinical esthetics and mimic the natural tooth mineral. Due to the ease of solid solution of the apatite lattice, rare earth doped apatite GCs are discussed for potential applications in optoelectronics and nuclear waste management. One of the drawbacks of the commercial apatite GCs used in orthopedics is the lack of resorbability; therefore, the review provides a direction for future research in the field.

show abstract

“…Klinik ve deneysel çalışmalarda aliminyumun kemik döngüsünü inhibe ettiği, osteoblast ve aktivitesi ve farklılaşmasını azalttığı gösterilmiştir. Aynı zamanda yüksek dozdaki alüminyum maruziyeti PTH supresyonu yaparak kalsiyum homeostazını etkilemektedir (38)(39)(40).…”

Section: Aliminyumunclassified

Toxic Effects of Heavy Metals on Bone Tissue

Akbal¹,

Reşorlu²,

Savaş³

2015

Tod

View full text Add to dashboard Cite

Ağır metaller doğada yaygın olarak bulunur. Çevresel ve mesleki nedenlerle ağır metallere maruz kalındığı zaman çeşitli sistemlerde toksik etkiler ortaya çıkabilir. Ağır metallere akut ve kronik maruziyette farklı klinik bulgular ortaya çıkar. Birçok ağır metalin primer doku organı kemiktir ve kronik maruziyette kemik dokuda toksik etkiler oluşturur. Bu makalede maruziyetine sık rastlanan ağır metallerin kemik üzerine toksik etkilerinin gözden geçirilmesi amaçlandı. (

show abstract

Aluminum administration in the Rat separately affects the osteoblast and Bone mineralization

Cited by 74 publications

References 28 publications

Calcium Deficiency Reduces Circulating Levels of FGF23

Calcium Deficiency Reduces Circulating Levels of FGF23

Apatite Glass-Ceramics: A Review

Toxic Effects of Heavy Metals on Bone Tissue

Contact Info

Product

Resources

About